We are live on ! Find out more
VRX

VALEANT PHARMACEUTICALS INTL
VRX

Delisted

VRX was delisted on the 27th of September, 2010.

Back to rankings

1 hedge funds and large institutions have $380K invested in VALEANT PHARMACEUTICALS INTL in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCP
Syntal Capital Partners
Texas
+$380K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
SCP
1
Syntal Capital Partners
Texas
$380K +$380K +9,500 New

VRX Hedge Fund Activity: Q3 2019 in Review

1 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in VALEANT PHARMACEUTICALS INTL (VRX) for Q3 2019, worth a combined $380K.

Buyers outnumbered sellers: 1 fund opened new VRX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Syntal Capital Partners, opening a new position worth an estimated $380K.

  • 1 institutional investor held VALEANT PHARMACEUTICALS INTL (VRX) as of Q3 2019, up from 0 in Q2 2019.
  • Funds reported $380K of VALEANT PHARMACEUTICALS INTL stock for Q3 2019.
  • 1 fund opened new VALEANT PHARMACEUTICALS INTL positions in Q3 2019 and 0 closed out, a net change of +1 holder.
  • The largest VALEANT PHARMACEUTICALS INTL buyer in Q3 2019 was Syntal Capital Partners, an estimated $380K added.

Based on aggregated 13F filings for Q3 2019.